

### CLAIM LISTING

Claim 1 (Previously Presented) A composition for treating impaired neurological function or treating deteriorating neurological function in the body of a human, comprising effective amounts of:

- (A) at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body;
- (B) at least one antioxidant for scavenging free radicals in at least one pathway in the body;
- (C) at least one agent for treating or maintaining membrane function and structure in the body;
- (D) at least one agent for treating or maintaining normal neurotransmitter function in the body;
- (E) at least one agent for down-regulating cortisol action; and
- (F) at least one agent for suppressing activation of apoptotic pathways in the body.

Claim 2 (Withdrawn) A composition according to claim 1, wherein component (A) comprises one or more members selected from the group consisting of co-enzyme Q10, idebenone, taurine, acetyl L-carnitine, nicotinamide adenine dinucleotide, phosphatidyl serine, B-vitamins, vinpocetine, oral creatine, cytidine-5'-diphosphocholine, ribose and alpha lipoic acid.

Claim 3 (Withdrawn) A composition according to claim 2, wherein component (A) comprises a combination of oral creatine and ALA in an oral creatine:ALA weight ratio of from about 1:30 to about 2500:1.

Claim 4 (Withdrawn) A composition according to claim 1, wherein component (B) comprises one or more antioxidants selected from the following: idebenone, co-enzyme Q10, vitamin E, ALA, vitamin C, carnosine, tocotrienols, flavonoids, ALC, vinpocetine, selenium, lycopene, creatine, arginine, taurine, cysteine, nicotinamide adenine dinucleotide, resveratrol, ginkgo biloba, oligomeric proanthocyanidins, and phenolic antioxidants.

Claim 5 (Withdrawn) A composition according to claim 4, wherein component

Serial No. 09/837,562  
Supplemental Submission Responsive To  
Advisory Action Dated 12/16/2003

Page 2

(B) comprises a combination of taurine and cysteine at a taurine:cysteine weight ratio of from about 1:20 to about 60:1.

Claim 6 (Withdrawn) A composition according to claim 1, wherein component (C) comprises one or more members selected from the group consisting of: gamma linolenic acid; highly polyunsaturated long chain fatty acids; CDP-choline; methyl donors; S-adenosyl methionine, antioxidants and sphingosine.

Claim 7 (Withdrawn) A composition according to claim 6, wherein component (C) is a highly polyunsaturated long chain fatty acid selected from the group consisting of: docosahexanoic acid, phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, and phosphatidyl inositol.

Claim 8 (Withdrawn) A composition according to claim 7, wherein component (C) comprises a combination of docosahexanoic acid and phosphatidyl serine at docosahexanoic acid:phosphatidyl serine weight ratio of from about 1000:1 to about 1:100.

Claim 9 (Withdrawn) A composition according to claim 1, wherein component (D) comprises one or more agents selected from the group consisting of: (1) an agent for synthesis of neurotransmitters; (2) an agent for stimulation of production and secretion of neurotransmitters; (3) an agent for inhibition of enzymes used to degrade various neurotransmitter molecules within the region of the synaptic cleft; (4) a re-uptake inhibitor; (5) an agent that facilitates improved binding at the receptor site; (7) an agent for induction of enzymes used to synthesize neurotransmitters; and (8) an agent for augmentation of neurotransmitter receptor sites.

Claim 10 (Withdrawn) A composition according to claim 9, wherein component (d) comprises one or more agents selected from the group consisting of: choline, CDP-choline, phosphatidyl choline, DMAE, amino acids, phosphatidyl serine, vinpocetine, hyperfine A, Ritalin, peroxide, soy phytoestrogens, and SAME.

Claim 11 (Withdrawn) A composition according to claim 10, wherein component (D) comprises a combination of DMAE and huperzine A at a DMAE:huperzine weight ratio of from about 2000:1 to about 67:1.

Claim 12 (Withdrawn) A composition according to claim 1, wherein component (E) comprises one or more agents selected from the group consisting of phosphatidyl

Serial No. 09/837,562  
Supplemental Submission Responsive To  
Advisory Action Dated 12/16/2003

Page 3

serine, dehydroepiandrosterone, melatonin, and pyridoxine.

Claim 13 (Withdrawn) A composition according to claim 1, wherein component (F) comprises one or more agents selected from the group consisting of: vinpocetine, huperzine A, magnesium, calcium channel blockers, resveratrol, pycnogenol, and lycopene.

Claim 14 (Withdrawn) A composition according to claim 14, wherein component (F) comprises huperzine A and vinpocetine at a huperzine A:vinpocetine weight ratio of from about 1:2 to about 1:200.

Claim 15 (Withdrawn) A composition according to claim 1, further comprising one or more of the following ingredients:

- (G) at least one agent for suppressing inflammation in the body;
- (H) at least one agent for normalizing or maintaining vascular wall function and structure in the body;
- (I) at least one agent for normalizing or maintaining function of nerve growth factors and/or neurotropic factors in the body;
- (J) at least one agent for suppressing toxic metal ionic effects;
- (K) at least one agent for normalizing or maintaining methyl metabolism in the body;
- (L) at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and
- (M) at least one agent for up-regulating activity of heat shock proteins in the body.

Claim 16 (Withdrawn) A composition according to claim 15, wherein component (G) comprises one or more agents selected from the group consisting of: COX-2 inhibitors, CDP-choline, phosphatidyl serine, dehydroepiandrosterone, melatonin, pyridoxine, magnesium, gamma linolenic acid, long chain omega 3 fatty acids, insulin-sensitizing agents, antioxidants and vitamin C.

Claim 17 (Withdrawn) A composition according to claim 15, wherein component (H) comprises one or more agents selected from the group consisting of magnesium, L-arginine, L-taurine, antioxidants, insulin-sensitivity enhancers, long chain polyunsaturated

fatty acids, vinpocetine, creatine, choline, betaine, vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, folic acid, supplemental potassium, dehydroepiandrosterone, phosphatidyl serine, S-adenosyl methionine, zinc and selenium.

Claim 18 (Withdrawn) A composition according to claim 15, wherein component (I) comprises one or more agents selected from the group consisting of estrogenic compounds, idebenone, and propentofylline.

Claim 19 (Withdrawn) A composition according to claim 15, wherein component (J) comprises one or more agents selected from the group consisting of desferroximine, alpha-lipoic acid, zinc, silicon and polyphenolic antioxidants.

Claim 20 (Withdrawn) A composition according to claim 15, wherein component (K) comprises one or more agents selected from the group consisting of dehydroepiandrosterone, phosphatidyl serine, S-adenosyl methionine, choline, folic acid, vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, betaine, zinc, selenium and creatine.

Claim 21 (Withdrawn) A composition according to claim 15, wherein component (L) comprises (a) one or more agents which down-regulate glutamatergic tone and/or (b) one or more insulin-sensitizing agents.

Claim 22 (Withdrawn) A composition according to claim 21, wherein component (L) comprises one or more agents selected from the group consisting of huperzine A, magnesium and chromium.

Claim 23 (Withdrawn) A composition according to claim 15, comprising: thiamine, riboflavin, niacin, carnosine, pyridoxine, folic acid, vitamin B<sub>12</sub>, biotin, pantothenic acid, vitamin C, vitamin E, magnesium, zinc, selenium, chromium, potassium, oligomeric proanthocyanidin, cysteine, taurine, acetyl-L-carnitine, creatine monohydrate, DMAE, choline, inositol, phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, docosahexanoic acid, vinpocetine, huperzine A, coenzyme Q10, L-arginine, idebenone, gamma linoleic acid, silicon, alpha-lipoic acid, resveratrol, soy isoflavones, CDP-choline, NADH, DHEA, melatonin, ribose, lycopene, betaine and ginkgo biloba.

Claim 24 (Previous Presented) A method for treating impaired neurological function or treating deteriorating neurological function in a human suffering from impaired

Serial No. 09/837,562  
Supplemental Submission Responsive To  
Advisory Action Dated 12/16/2003

Page 5

neurological function or deteriorating neurological function, comprising administering for a therapeutically effective period to said human an effective amount of a nutritional supplement composition comprising effective amounts of:

(A) at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body;

(B) at least one antioxidant for scavenging free radicals in at least one pathway in the body;

(C) at least one agent for treating or maintaining membrane function and structure in the body;

(D) at least one agent for treating or maintaining normal neurotransmitter function in the body;

(E) at least one agent for down-regulating cortisol action; and

(F) at least one agent for suppressing activation of apoptotic pathways in the body.

Claim 25 (Withdrawn) A method according to claim 24, wherein in the composition administered to said human, component (A) comprises one or more members selected from the group consisting of co-enzyme Q10, idebenone, taurine, acetyl L-carnitine, nicotinamide adenine dinucleotide, phosphatidyl serine, B-vitamins, vinpocetine, oral creatine, cytidine-5'-diphosphocholine, ribose and alpha lipoic acid.

Claim 26 (Withdrawn) A method according to claim 25, wherein in the composition administered to said human, component (A) comprises a combination of oral creatine and ALA in an oral creatine:ALA weight ratio of from about 1:30 to about 2500:1.

Claim 27 (Withdrawn) A method according to claim 24, wherein in the composition administered to said human, component (B) comprises one or more antioxidants selected from the following: idebenone, co-enzyme Q10, vitamin E, ALA, vitamin C, flavonoids, carnosine, tocotrienols, ALC, vinpocetine, selenium, lycopene, creatine, arginine, taurine, cysteine, nicotinamide adenine dinucleotide, resveratrol, ginkgo biloba, oligomeric proanthocyanidins, and phenolic antioxidants.

Claim 28 (Withdrawn) A method according to claim 27, wherein in the composition administered to said human, component (B) comprises a combination of

Serial No. 09/837,562

Supplemental Submission Responsive To  
Advisory Action Dated 12/16/2003

Page 6

taurine and cysteine at a taurine:cysteine weight ratio of from about 1:20 to about 60:1.

Claim 29 (Withdrawn) A method according to claim 24, wherein in the composition administered to said human, component (C) comprises one or more members selected from the group consisting of: gamma linolenic acid; highly polyunsaturated long chain fatty acids; CDP-choline; methyl donors; S-adenosyl methionine, antioxidants and sphingosine.

Claim 30 (Withdrawn) A method according to claim 29, wherein in the composition administered to said human, component (C) is a highly polyunsaturated long chain fatty acid selected from the group consisting of: docosahexanoic acid, phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, and phosphatidyl inositol.

Claim 31 (Withdrawn) A method according to claim 30, wherein in the composition administered to said human, component (C) comprises a combination of docosahexanoic acid and phosphatidyl serine at docosahexanoic acid:phosphatidyl serine weight ratio of from about 1000:1 to about 1:100.

Claim 32 (Withdrawn) A method according to claim 24, wherein in the composition administered to said human, component (D) comprises one or more agents selected from the group consisting of: (1) an agent for synthesis of neurotransmitters; (2) an agent for stimulation of production and secretion of neurotransmitters; (3) an agent for inhibition of enzymes used to degrade various neurotransmitter molecules within the region of the synaptic cleft; (4) a re-uptake inhibitor; (5) an agent that facilitates improved binding at the receptor site; (7) an agent for induction of enzymes used to synthesize neurotransmitters; and (8) an agent for augmentation of neurotransmitter receptor sites.

Claim 33 (Withdrawn) A composition according to claim 32, wherein in the composition administered to said human, component (D) comprises one or more agents selected from the group consisting of: choline, CDP-choline, phosphatidyl choline, DMAE, amino acids, phosphatidyl serine, vinpocetine, huperzine A, ritalin, pergolide, soy phytoestrogens, and SAME.

Claim 34 (Withdrawn) A method according to claim 33, wherein in the composition administered to said human, component (D) comprises a combination of DMAE and huperzine A at a DMAE:huperzine A weight ratio of from about 2000:1 to about

67:1.

Claim 35 (Withdrawn) A method according to claim 24, wherein in the composition administered to said human, component (E) comprises one or more agents selected from the group consisting of phosphatidyl serine, dehydroepiandrosterone, melatonin, and pyridoxine.

Claim 36 (Withdrawn) A method according to claim 24, wherein in the composition administered to said human, component (F) comprises one or more agents selected from the group consisting of: vinpocetine, huperzine A, magnesium, calcium channel blockers, resveratrol, pycnogenol, and lycopene.

Claim 37 (Withdrawn) A method according to claim 36, wherein in the composition administered to said human, component (F) comprises a combination of huperzine A and vinpocetine in a huperzine A:vinpocetine ratio of from about 1:2 to about 1:200.

Claim 38 (Withdrawn) A method according to claim 24, wherein the composition administered to said human further comprises one or more of the following ingredients:

(G) at least one agent for suppressing inflammation in the body;

(H) at least one agent for normalizing or maintaining vascular wall function and structure in the body;

(I) at least one agent for normalizing or maintaining function of nerve growth factors and/or neurotropic factors in the body;

(J) at least one agent for suppressing toxic metal ionic effects;

(K) at least one agent for normalizing or maintaining methyl metabolism in the body;

(L) at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and

(M) at least one agent for up-regulating activity of heat shock proteins in the body.

Claim 39 (Withdrawn) A method according to claim 38, wherein in the composition administered to said human, component (G) comprises one or more agents selected from the group consisting of: COX-2 inhibitors, CDP-choline, phosphatidyl serine,

Serial No. 09/837,562

Supplemental Submission Responsive To

Advisory Action Dated 12/16/2003

Page 8

dehydroepiandrosterone, melatonin, pyridoxine, magnesium, gamma linolenic acid, long chain omega 3 fatty acids, insulin-sensitizing agents, antioxidants and vitamin C.

Claim 40 (Withdrawn) A method according to claim 38, wherein in the composition administered to said human, component (H) comprises one or more agents selected from the group consisting of magnesium, L-arginine, L-taurine, antioxidants, insulin-sensitivity enhancers, long chain polyunsaturated fatty acids, vinpocetine, creatine, choline, betaine, vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, folic acid, supplemental potassium, dehydroepiandrosterone, phosphatidyl serine, S-adenosyl methionine, zinc and selenium.

Claim 41 (Withdrawn) A method according to claim 38, wherein in the composition administered to said human, component (I) comprises one or more agents selected from the group consisting of estrogenic compounds, idebenone, and propentofylline.

Claim 42 (Withdrawn) A method according to claim 38, wherein in the composition administered to said human, component (J) comprises one or more agents selected from the group consisting of desferroximine, alpha-lipoic acid, zinc, silicon and polyphenolic antioxidants.

Claim 43 (Withdrawn) A method according to claim 38, wherein in the composition administered to said human, component (K) comprises one or more agents selected from the group consisting of dehydroepiandrosterone, phosphatidyl serine, S-adenosyl methionine, choline, folic acid, vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, betaine, zinc, selenium and creatine.

Claim 44 (Withdrawn) A method according to claim 38, wherein in the composition administered to said human, component (L) comprises (a) one or more agents which down-regulate glutamatergic tone and/or (b) one or more insulin-sensitizing agents.

Claim 45 (Withdrawn) A method according to claim 44, wherein in the composition administered to said human, component (L) comprises one or more agents selected from the group consisting of huperzine A, magnesium and chromium.

Claim 46 (Withdrawn) A method according to claim 38, wherein the composition administered to said human comprises: thiamine, riboflavin, niacin, carnosine, pyridoxine, folic acid, vitamin B<sub>12</sub>, biotin, pantothenic acid, vitamin C, vitamin E, magnesium, zinc,



selenium, chromium, potassium, oligomeric proanthocyanidin, cysteine, taurine, acetyl-L-carnitine, creatine monohydrate, DMAE, choline, inositol, phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, docosahexanoic acid, vinpocetine, huperzine A, coenzyme Q10, L-arginine, idebenone, gamma linoleic acid, silicon, alpha-lipoic acid, resveratrol, soy isoflavones, CDP-choline, NADH, DHEA, melatonin, ribose, lycopene, betaine and ginkgo biloba.

Claim 47 (Withdrawn) A method according to claim 38, wherein the composition is administered on a daily basis to said human.

Claim 48 (Withdrawn) A method according to claim 38, wherein said therapeutically effective period of time is at least three weeks.

Claim 49 (Withdrawn) A method according to claim 38, wherein the effective amount of the composition is at least about 1 gram per serving.

Claim 50 (Withdrawn) A method according to claim 24, further comprising the step of having the human follow a stress reduction program which is effective in down-regulating the hypothalamic-pituitary-adrenal axis and lower cortisol levels.

Claim 51 (Withdrawn) A method according to claim 24, further comprising the step of having the human follow a cognitive retraining program.

Claim 52 (Withdrawn) A method according to claim 24, further comprising the step of having the human follow a dietary plan designed to maximize insulin and glucose metabolism.

Claim 53 (Previously Presented) A composition according to claim 1, wherein component (A) comprises B-vitamins.

Claim 54 (Previously Presented) A composition according to claim 1, wherein component (B) comprises ALA.

Claim 55 (Previously Presented) A composition according to claim 1, wherein component (C) comprises methyl donors.

Claim 56 (Previously presented) A composition according to claim 1, wherein component (D) comprises huperzine A.

Claim 57 (Previously Presented) A composition according to claim 1, wherein component (E) comprises pyridoxine.

Serial No. 09/837,562

Supplemental Submission Responsive To

Advisory Action Dated 12/16/2003

Page 10

Claim 58 (Previously Presented) A composition according to claim 1, wherein component (F) comprises vinpocetine.

Claim 59 (Previously Presented) A method according to claim 24, wherein component (A) of the composition comprises B-vitamins.

Claim 60 (Previously Presented) A method according to claim 24, wherein component (B) of the composition comprises ALA.

Claim 61 (Previously Presented) A method according to claim 24, wherein component (C) of the composition comprises methyl donors.

Claim 62 (Previously Presented) A method according to claim 24, wherein component (D) of the composition comprises huperzine A.

Claim 63 (Previously Presented) A method according to claim 24, wherein component (E) of the composition comprises pyridoxine.

Claim 64 (Previously Presented) A method according to claim 24, wherein component (F) of the composition comprises vinpocetine.